[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Dr Nair, India, Summary", "description": "How is the situation in India now, are you seeing a lot of cases?\n\nHow is the death rate, are there a lot of deaths, now and in the past weeks?\n\nWhat is the causes of deaths in COVID patients, is it mostly respiratory failure?\n\nHave you had difficulties with supplies of oxygen and drugs?\n\nWhat are the local drivers of infection, are people flowing mask wearing and social distancing?\n\nAre you able to test all of the patients you suspect have COVID?\n\nHow are you treating patients with mild and more severe disease?\n\nWhat drugs do you use in addition to steroids?\n\nIs ivermectin effective to treat COVID?\n\nDo many patients develop secondary bacterial infection after COVID?\n\nDo you think many people might develop long covid with longer term sequala?", "link": "https://www.youtube.com/watch?v=YQdKsLZjmaQ", "date_published": "2021-05-01 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Dr Nair, Infectious Diseases Consultant, India", "description": "How is the situation in India now, are you seeing a lot of cases?\n\nHow is the death rate, are there a lot of deaths, now and in the past weeks?\n\nWhat is the causes of deaths in COVID patients, is it mostly respiratory failure?\n\nHave you had difficulties with supplies of oxygen and drugs?\n\nWhat are the local drivers of infection, are people flowing mask wearing and social distancing?\n\nAre you able to test all of the patients you suspect have COVID?\n\nHow are you treating patients with mild and more severe disease?\n\nWhat drugs do you use in addition to steroids?\n\nIs ivermectin effective to treat COVID?\n\nDo many patients develop secondary bacterial infection after COVID?\n\nDo you think many people might develop long covid with longer term sequala?", "link": "https://www.youtube.com/watch?v=Hd96VTr5TDw", "date_published": "2021-05-01 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Two vaccine shots, implications", "description": "Vary greatly on the two sides of the pond. US goes one way, the UK another.\nUK, awaiting rule change for 2 dosers\n\nhttps://www.bbc.co.uk/news/health-56929483\n\nIndoor gatherings\n\nWales, 3rd May\n\nEngland, Scotland 17th May\n\nNI, 24th May\n\nProf Jonathan Van-Tam\n\nIf two people who both had two doses of vaccine, \n\nand have both served at least 14 days after their second dose, \n\nthen I would be highly confident scientifically that if they were reputable vaccines then \nindeed it would be incredibly safe for those two people to meet\n\nPaul Hunter, Professor of Medicine, University of East Anglia\n\nTrue just now with B117\n\nThe issue is variants with escape mutations that are less affected by the vaccine, \nand we haven't come to clear understanding of what those risks are\n\nUK, Indian or South African variants yet to make an impact\n\nhttps://covid.joinzoe.com/post/indian-or-south-african-variants-yet-to-make-an-impact\n\n22nd April\n\nIndia\nhttps://www.aljazeera.com/news/2021/5/1/fire-in-hospitals-intensive-care-kills-18-in-indias-gujarat\n\nhttps://www.washingtonpost.com/nation/2021/04/29/coronavirus-covid-live-updates-us/\n\nCases, + 379,257 + 386,452 + 401,993 = 19,100,000\n\nDeaths, + 3,645 + 3,523 = 211,853\n\nVaccinations\n\nAll adults now eligible\n\nWas over 45s\n\nOne dose, 10%\n\nTwo doses 1.5%\n\nIndia / Australia\n\nCriminal offence for citizens to return home, from Monday\n\nIndia / US\n\nRestrictions from 4th May\n\nMost non-US citizens, India within the last 14 days will not be allowed into US\n\nIndia / France\n\nFirst case was detected in Lot-et Garonne, in southwestern France\n\nThe patient is currently hospitalised in Bordeaux\n\nhttps://www.lexpress.fr/actualite/societe/sante/ce-que-l-on-sait-des-differents-cas-de-variants-indiens-detectes-en-france_2149875.html\n\nTwo more cases in the south east \u2013 in the Marseille d\u00e9partement of Bouches-du-Rh\u00f4ne.\n\nTwo people returning from India without any link to one another\n\n10-day quarantine for arrivals from India, Brazil, South Africa, Chile and Argentina\n\nhttps://www.thelocal.fr/20210430/three-cases-of-the-indian-variant-of-covid-detected-in-france/?utm_source=piano&utm_medium=email&utm_campaign=213&tpcc=newsletter_members&pnespid=1fBz_aVRDRWNUoF70GTcVJXtQlLxVSWUNbDvEHY\n\nSequencing rate\n\nhttps://www.washingtonpost.com/nation/2021/04/29/coronavirus-covid-live-updates-us/#link-UVLBM3S2DFH65KGAD5772HMJ6Q\n\nIceland, 78.8%\n\nAustralia, 60.3%\n\nNew Zealand, 48.5%\n\nDenmark, 20.2%\n\nTaiwan, 16%\n\nUK, 8.7%\n\nNorway, 5.6%\n\nVietnam, 5.5%\n\nUS, 1%\n\nIndia (102) 18,000,000 (10,626) 0.06%\n\nU.S. government, $100 million worth of supplies\n\nUS State Department, U.S. citizens to leave India as soon as it is safe to do\n\nhttps://in.usembassy.gov/health-alert/\n\nSpread from cities to small towns\n\nhttps://www.bbc.co.uk/news/world-asia-india-56913047\n\nSpread now occurring, but underreported\n\nCorruption and black markets\n\nMedical debt already a big problem in India\n\nRemdesivir problem\n\nhttps://bnf.nice.org.uk/medicinal-forms/remdesivir.html\n\nRemdesivir for the Treatment of Covid-19 \u2014 Final Report (NEJM, 5th November 2020)\n\nhttps://www.nejm.org/doi/full/10.1056/nejmoa2007764\n\nDouble-blind, randomized, placebo-controlled trial of intravenous remdesivir\n\nTen day course\n\nHospitalized with Covid-19 with evidence of lower respiratory tract infection\n\nN = 1062\n\nRemdesivir group, 541\n\nPlacebo, 521\n\nRemdesivir group, n = 541\n\nMedian recovery time, 10 days\n\nNeed for oxygen, 13 days\n\nMortality by day 15 was 6.7%\n\nMortality by day 29 was 11.4%\n\nPlacebo controls, n = 521\n\nMedian recovery time 15 days\n\nNeed for oxygen, 21 days\n\nMortality by day 15 was 11.9%\n\nMortality by day 29 was 15.2% (HR = 0.73)\n\nSerious adverse events\n\nRemdesivir group, 24.6%\n\nPlacebo group, 31.6%\n\nSerious adverse events in placebo group, 31.6%", "link": "https://www.youtube.com/watch?v=hVo0pVC9Swk", "date_published": "2021-05-01 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Australia update with Dr Farrier", "description": "Update on prevention of community transmission in Australia, followed by vaccinations update. Discussions on the Indian situation and the prospects for viral elimination.\nhttps://www.wa.gov.au/government/covid-19-coronavirus\nAlso a recent survey on people wanting the vaccine in Australia\"\nhttps://www.msn.com/en-au/money/markets/only-40percent-of-australians-want-the-astrazeneca-vaccine-what-could-this-mean-for-csl-asxcsl/ar-BB1gcgqj?ocid=sf", "link": "https://www.youtube.com/watch?v=UgylurAiye4", "date_published": "2021-04-30 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "UK vaccines data", "description": "Here\u2019s what we know so far about the after effects of the Pfizer COVID vaccine\n\nhttps://covid.joinzoe.com/post/covid-vaccine-pfizer-effects\n\nHere\u2019s what we know so far about the after effects of the Oxford AstraZeneca COVID vaccine\n\nhttps://covid.joinzoe.com/post/covid-vaccine-astrazeneca-effects\n\nHow to tell the difference between COVID-19 symptoms and vaccine after effects\n\nhttps://covid.joinzoe.com/post/covid-symptoms-or-vaccine-after-effects\n\nVaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study\n\nhttps://covid.joinzoe.com/post/covid-vaccine-data-lancet\n\nhttps://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00224-3/fulltext\n\nPfizer-BioNTech (BNT162b2)\n\nOxford-AstraZeneca (ChAdOx1 nCoV-19)\n\nSafety and effectiveness in UK community setting\n\n1,607,620 users (2\u00b74% of the UK population)\n\nMethods\n\nProspective observational study\n\nSelf-reported systemic and local side-effects within 8 days\n\nAfter one or two doses\n\nInfection rates, after vaccine, diagnosed by PCR or lateral flow\n\nUnvaccinated controls\n\nFindings\n\nDec 8th 2020, and March 10th 2021\n\nVaccinated reporters, n = 627\u2009383\n\nReactogenicity, (common, expected)\n\nSystemic side-effects\n\nFatigue and headache (about 4% each)\n\nMost frequently within the first 24 h\n\nLasted a mean of 1\u00b701 days \n\nFever\n\nChills or shivers\n\nNausea\n\nDiarrhoea\n\nMuscle pains\n\nJoint pains\n\nLocal side effects\n\nTenderness and local pain\n\nRedness\n\nSwollen armpit glands\n\nWarmth\n\nItch\n\nBruising\n\nPfizer\n\nOne dose, 282,\u2009103 (13% SSE) (71.9% LSE)\n\nTwo doses, 28,\u2009207 (22% SSE) (68.5% LSE)\n\nMedian, 41 days apart\n\nOxford AZ\n\nOne dose, 345\u2009280 (33.7% SSE) (58.7% LSE)\n\nIn those with past infection after Pfizer\n\nSSE x 2.9\n\nLSE x 1.2\n\nIn those with past infection after Oxford AZ\n\nSSE x 1.6\n\nLSE x 1.4\n\nVaccinated people who became infected\n\nVaccine group, 3,106 of 103,622\n\nUnvaccinated controls, 50,340 of 464,356\n\nReductions in infection risk\n\nStarted at 12 days after the first dose, to 21 days\n\nReaching - 60% Oxford AZ\n\nReaching - 58% for the Pfizer\n\nLonger term benefits of vaccination after Pfizer\n\nRR, 21 to 44 days - 69%\n\nRR, 45 to 59 days, - 72%\n\nIn conclusion, short-term adverse effects of both vaccines are moderate in frequency, mild in severity, and short-lived. \n\nAdverse effects are more frequently reported in younger individuals, women, and among those who previously had COVID-19. \n\nThe post-vaccine symptoms (both systemic and local) often last 1\u20132 days from the injection. \n\nOur data could be used to inform people on the likelihood of side-effects on the basis of their age and sex and the type of vaccine being administered. \n\nFurthermore, our data support results from randomised controlled trials in a large community-based scenario showing evidence of reduction in infection after 12 days and substantial protection after 3 weeks.", "link": "https://www.youtube.com/watch?v=9t4y1-gSj_U", "date_published": "2021-04-30 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]